News

New Leaf Venture Partners led the financing, which included new investors Frazier Healthcare Partners, Longitude Capital, and Osage University Partners. Existing investors Adams Street Partners, LVP Life Science

DRM01 is a novel, small molecule designed to inhibit sebum production after topical application to treat acne. It is designed to target acetyl coenzyme-A carboxylase, an enzyme that

The Phase 1 portion of the study will test the safety and tolerability of escalating doses of X4P-001 in combination with Inlyta (axitinib), a kinase inhibitor approved for

The distribution rights to fenofibrate were acquired earlier this year and, as previously announced, ANI had expected to transition these products to the ANI label in the second

WAVE’s DMD program is based on preclinical data demonstrating an approximate 25-fold improvement in exon-skipping efficiency compared to drisapersen and eteplirsen, suggesting the potential for improved potency and

Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit

Under the deal, Incyte will make a $140m upfront payment to Ariad plus pay royalties of up to 50% on European sales of Iclusig. Incyte will also take

Janssen Biotech and AbbVie company Pharmacyclics are jointly developing and commercializing Imbruvica, which blocks a specific protein called Bruton’s tyrosine kinase. The Imbruvica labeling now includes OS results

Hotung Group, and CDIB Capital Management, led the round with continued participation from existing investors, Eminent II VC, Hua Nan Venture Capital, President International Development and UMC Capital